Suggestions
Vanessa Michelini
IBM Distinguished Engineer - Master Inventor l Working in the intersection of technology, business and science to give hope and save lives - Watson for Genomics Director
Vanessa Michelini is a technology executive and innovator currently serving as the VP of Engineering, Lab Informatics and Genomics Platform at Natera.2 Based in Boca Raton, Florida, she has an impressive background in technology and genomics.1
Professional Background
Michelini has held several notable positions and received numerous accolades throughout her career:
- IBM Distinguished Engineer: Recognized in April 2013, one of the highest technical recognitions in IBM and the industry.1
- IBM Master Inventor: Awarded in November 2011.1
- IBM Corporate Technical Award: Received in April 2017 for outstanding technical innovations in Watson for Genomics.1
Expertise and Achievements
Michelini's expertise spans several areas:
- Genomics and Bioinformatics: She is passionate about applying cutting-edge technology to genomics and precision medicine.13
- Innovation: Michelini has been recognized for her innovative contributions, including four patent awards from the Society of Women Engineers.1
- Leadership: She currently leads a team at Natera, shaping the future of precision medicine.3
Recognition
Michelini has received several honors for her work:
- Outstanding Technical Contributions in Industry: Awarded by Women of Color (WOC) STEM in August 2020.1
- IBM Certified Executive: Issued in May 2020.1
- Member of IBM Academy of Technology: Since January 2014.1
Skills and Languages
Michelini is multilingual, with proficiency in:
- English (native or bilingual)
- Portuguese (native or bilingual)
- Spanish (limited working proficiency)
- French (elementary proficiency)1
Her diverse skill set and extensive experience make Vanessa Michelini a prominent figure in the fields of technology and genomics.
Highlights
Great news! Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer.
#innovation #signatera #genomics
“ctDNA is emerging as a potential biomarker for informing adjuvant treatment decisions and assessing treatment response in metastatic disease in real-time,” said Zeynep Eroglu, M.D., medical oncologist in the department of cutaneous oncology at Moffitt Cancer Center and lead author of the study.
#innovation #genomics #signatera
